




Executive summary

Transforming healthcare with Al

The impact on the workforce and organisations







Foreword

Artificial intelligence (AI) has the potential to transform how care is delivered. It can support improvements in care outcomes, patient experience and access to healthcare services. It can increase productivity and the efficiency of care delivery and allow healthcare systems to provide more and better care to more people. AI can help improve the experience of healthcare practitioners, enabling them to spend more time in direct patient care and reducing burnout. Finally, it can support the faster delivery of care, mainly by accelerating diagnosis time, and help healthcare systems manage population health more proactively, allocating resources to where they can have the largest impact.

The implications of introducing and scaling AI in healthcare have been much debated in recent years. The full potential of AI is still being discussed, but questions have been raised about its potential impact on practitioners and certain specialties, while issues around ethics, use of personal data and AI-related risks are also being debated. At the same time, healthcare investments in AI are increasing, creating or accentuating disparities in the adoption of innovation in healthcare, and raising questions around the role that health systems, public and private players and individual healthcare practitioners can, or should, play in ensuring citizens fully reap the benefits of AI.

This joint report between EIT Health and McKinsey & Company aims to build on the existing literature and thinking on the potential of AI in healthcare, going a step further in helping define the impact of AI on healthcare practitioners, and the implications of introducing and scaling AI for healthcare organisations and healthcare systems, with a particular focus on Europe and EU Member States. It does so by bringing together the McKinsey Global Institute's (MGI) research programme on the future of work with new analyses on the future of work in healthcare, focused on Europe. This is complemented by 62 interviews of public- and private-sector decision makers and thought leaders across Europe, North America and Asia, and an in-depth survey of 175 healthcare professionals, health investors and AI startup founders and other executives, conducted between December 2019 and January 2020.

The report aims to provide not only a comprehensive 'macro' perspective on AI in healthcare, but also ground this view in the reality of the people tasked with making AI happen in healthcare delivery today, listening to their voices, hopes, frustrations and suggestions. While recognising that it is still early days in terms of fully understanding the potential role of AI in healthcare, the report helps define the boundaries between aspiration, reality and hype, providing intriguing insights into how much of the AI in healthcare narrative is a reality and how healthcare professionals, startup executives and investors prioritise and navigate the choppy waters of innovation, in Europe and beyond.

The report is a collaboration between EIT Health and McKinsey & Company:

- EIT Health is a Knowledge and Innovation Community supported by the European Institute
 of Innovation and Technology (EIT), an EU body created to find solutions to pressing global
 challenges. EIT is an integral part of the European Union's Framework Programme for Research
 and Innovation. EIT Health brings together experts from business, research and education to
 form dynamic cross-border collaborations, helping create an optimal environment for healthcare
 innovation to flourish.
- The McKinsey Center for Government (MCG) is a global hub for research, collaboration and innovation in government productivity and performance, under the auspices of which this report is being published. Further analysis for this report came from QuantumBlack, McKinsey's advanced analytics firm; and McKinsey's Healthcare Systems and Services, and Pharmaceutical and Medical Products practices. The analyses also drew from research on the impact of automation on jobs by MGI, McKinsey's independent think tank, established in 1990 to develop a deeper understanding of the evolving global economy and cited as the world's leading private-sector think tank in the 2018 Global Go To Think Tank Index Report.

The research was led by Jorge Fernández García, Director of Innovation, EIT Health; Dr. Angela Spatharou, Partner, Healthcare Systems and Services, McKinsey & Company; Jonathan Jenkins, Senior Principal, QuantumBlack; and Solveigh Hieronimus, Partner, McKinsey & Company and co-leader of the MCG.

Steering group guidance was provided by Jan-Philipp Beck, CEO, EIT Health; and from McKinsey & Company, by Dr. Penny Dash, Senior Partner and leader of the Healthcare Systems and Services practice in Europe; Dr. Nicolaus Henke, Senior Partner and Chairman of QuantumBlack; Dr. Chris Llewellyn, Senior Partner and global leader of Digital and Al services, Pharmaceutical and Medical Products practice; and Dr. Jaana Remes, Partner, MGI.

The team was comprised of Maria Fernández Albizuri, EIT Health and Dr. Mareike Herzog, Dr. Franziska Galiè and Will Taylor, McKinsey & Company; Gurneet Singh Dandona, Alok Singh, Shagun Narula and EB Armstrong, MGI; and Paul Mears, Senior Healthcare Advisor, McKinsey & Company.

This report contributes to the goal to help healthcare practitioners, public- and private-sector healthcare decision makers, policy makers, regulators, healthcare investors and innovators better understand the latest thinking on AI in healthcare, its potential impact on practitioners and healthcare systems and, in so doing, prioritise areas of focus in introducing or scaling AI in healthcare. As with all our research, this work is independent and has not been commissioned or sponsored in any way by external parties. While we are grateful for all the input we have received, the report and the views expressed here reflect the outcome of the EIT Health and McKinsey & Company collaboration alone.

Jorge Fernández García

Director of Innovation, EIT Health

Solveigh Hieronimus

Partner, McKinsey & Company, co-leader, MCG **Dr. Angela Spatharou**

Partner, McKinsey & Company

Jan-Philipp Beck CEO.

EIT Health

Jonathan Jenkins

Senior Principal, QuantumBlack



Executive summary

Healthcare is one of the major success stories of our times. Medical science has improved rapidly, raising life expectancy around the world, but as longevity increases, healthcare systems face growing demand for their services, rising costs and a workforce that is struggling to meet the needs of its patients.

Demand is driven by a combination of unstoppable forces: population ageing, changing patient expectations, a shift in lifestyle choices, and the neverending cycle of innovation being but a few. Of these, the implications from an ageing population stand out. By 2050, one in four people in Europe and North America will be over the age of 65 – this means the health systems will have to deal with more patients with complex needs. Managing such patients is expensive and requires systems to shift from an episodic care-based philosophy to one that is much more proactive and focused on long-term care management.

Healthcare spending is simply not keeping up. Without major structural and transformational change, healthcare systems will struggle to remain sustainable. Health systems also need a larger workforce, but although the global economy could create 40 million new health-sector jobs by 2030, there is still a projected shortfall of 9.9 million physicians, nurses and midwives globally over the same period, according to the World Health Organization. We need not only to attract, train and retain more healthcare professionals, but we also need to ensure their time is used where it adds most value – caring for patients.

Building on automation, artificial intelligence (AI) has the potential to revolutionise healthcare and help address some of the challenges set out above. There are several definitions of AI, but this report draws from a concise and helpful definition used by the European Parliament, "AI is the capability of a computer program to perform tasks or reasoning processes that we usually associate with intelligence in a human being." AI can lead to better care outcomes and improve the productivity and efficiency of care delivery. It can also improve the day-to-day life of healthcare practitioners, letting them spend more time looking after patients and in so doing, raise staff morale and improve retention. It can even get life-saving treatments to market faster. At the same time, questions have been raised about the impact AI could have on patients, practitioners and health systems, and about its potential risks; there are ethical debates around how AI and the data that underpins it should be used.

This EIT Health and McKinsey & Company report aims to contribute to the debate surrounding Al in healthcare, specifically looking at how practitioners and organisations will be affected. It aims to cast light on the priorities and trade-offs for different parts of the healthcare system in Europe and beyond. The report draws on proprietary research and analyses undertaken by EIT Health and McKinsey & Company. This includes work by the McKinsey Global Institute (MGI) on the future of work in the era of automation and AI,³ analysing the impact on healthcare practitioners in Europe; a series of one-to-one interviews with 62 healthcare and other leaders with experience in AI and digital health, and an online survey of 175 healthcare professionals, healthcare investors and AI startup founders and other executives. AI in healthcare being a fast-moving field, the report provides a unique vantage point from the frontline of healthcare delivery and innovation today and the latest view from a wide array of stakeholders on AI's potential, the real state of play today, and what is holding us back.

Last, to highlight where AI is already having an impact in healthcare, the report also looks at detailed examples of existing AI solutions in six core areas where AI has a direct impact on the patient and three areas of the healthcare value chain that could benefit from further scaling of AI (Exhibit 1).

Exhibit 1 - Areas of impact for AI in healthcare



Improving population-health management

Improving operations

Strengthening innovation

In doing so, the report provides a unique contribution to the debate on the impact of AI in healthcare in four ways: 1) decision makers' view of the state-of-play in this fast-moving field, where developments from just 12 months ago are considered "old news"; 2) a robust new methodology to evaluate the impact of automation and AI on specific skills and activities in healthcare in Europe; 3) a substantial review of use cases that illustrate the potential that AI is already on track to deliver; 4) a unique view from the frontline, hearing from healthcare professionals, investors and startup executives on where the real potential, opportunities and barriers lie.

The report does not attempt to cover all facets of this complex issue, in particular the ethics of AI or managing AI-related risks, but does reflect the efforts on this important topic led by EIT Health and other EU institutions. Equally, while it acknowledges the potential disruptive impact of personalisation on both healthcare delivery and healthcare innovation in the future (e.g., in R&D), the report focuses primarily on the impact of AI on healthcare professionals and organisations, based on the use cases available today.

Last, Al is in its infancy and its long-term implications are uncertain. Future applications of Al in healthcare delivery, in the approach to innovation and in how each of us thinks about our health, may be transformative. We can imagine a future in which population-level data from wearables and implants change our understanding of human biology and of how medicines work, enabling personalised and real-time treatment for all. This report focuses on what is real today and what will enable innovation and adoption tomorrow, rather than exploring the long-term future of personalised medicine. Faced with the uncertainty of the eventual scope of application of emerging technologies, some short-term opportunities are clear, as are steps that will enable health providers and systems to bring benefits from innovation in Al to the populations they serve more rapidly.

Al in healthcare today

More data, better data, more connected data

What do we mean by Al in healthcare? In this report we include applications that affect care delivery, including both how existing tasks are *performed* and how they are *disrupted* by changing healthcare needs or the processes required to address them. We also include applications that enhance and improve healthcare delivery, from day-to-day operational improvement in healthcare organisations to population-health management and the world of healthcare innovation. It's a broad definition that covers natural language processing (NLP), image analysis and predictive analytics based on machine learning. As such, it illustrates a spectrum of Al solutions, where encoding clinical guidelines or existing clinical protocols through a rules-based system often provides a starting point, which then can be *augmented* by models that learn from data.

Al is now top-of-mind for healthcare decision makers, governments, investors and innovators, and the EU itself. An increasing number of governments have set out aspirations for Al in healthcare, in countries as diverse as Finland, Germany, the UK, Israel, China, and the United States and many are investing heavily in Al-related research. The private sector continues to play a significant role, with venture capital (VC) funding for the top 50 firms in healthcare-related Al reaching \$8.5 billion, and big tech firms, startups, pharmaceutical and medical-devices firms and health insurers, all engaging with the nascent Al healthcare ecosystem.

Geographically, the dynamics of AI growth are shifting. The US still dominates the list of firms with highest VC funding in healthcare Al to date, and has the most completed Al-related healthcare research studies and trials. But the fastest growth is emerging in Asia, especially China, where leading domestic conglomerates and tech players have consumer-focused healthcare AI offerings and Ping An's Good Doctor, the leading online health-management platform already lists more than 300 million users. Europe, meanwhile, benefits from the vast troves of health data collected in national health systems and has significant strengths in terms of the number of research studies, established clusters of innovation and pan-European collaborations, a pan-European approach to core aspects of AI (e.g., ethics, privacy, "trustworthy AI") and an emerging strategy on how to ensure the "EU way" for AI helps deliver the advantages for AI to its population. Yet, at the same time, valuable datasets are not linked, with critical data-governance, access and security issues still needing to be clarified, delaying further adoption. European investment and research in AI are strong when grouped together but fragmented at the country or regional level. Overall, there is a significant opportunity for EU health systems, but Al's full potential remains to be explored and the impact on the ground remains limited. A surprising 44 percent of the healthcare professionals we surveyed - and these were professionals chosen based on their engagement with healthcare innovation - had never been involved in the development or deployment of an Al solution in their organisation.

Growing number of use cases

While there are widespread questions on what is real in Al in healthcare today, this report looked at 23 applications in use today and provides case studies of 14 applications already in use. These illustrate the full range of areas where Al can have impact: from apps that help patients manage their care themselves, to online symptom checkers and e-triage Al tools, to virtual agents that can carry out tasks in hospitals, to a bionic pancreas to help patients with diabetes. Some help improve healthcare operations by optimising scheduling or bed management, others improve population health by predicting the risk of hospital admission or helping detect specific cancers early enabling intervention that can lead to better survival rates; and others even help optimise healthcare R&D and pharmacovigilance. The scale of many solutions remains small, but their increasing adoption at the health-system level indicates the pace of change is accelerating. In most cases, the question is less whether Al can have impact, and more how to increase the potential for impact and, crucially, how to do so while improving the user experience and increasing user adoption.

Three phases of scaling AI in healthcare

We are in the very early days of our understanding of Al and its full potential in healthcare, in particular with regards to the impact of Al on personalisation. Nevertheless, interviewees and survey respondents conclude that over time we could expect to see three phases of scaling Al in healthcare, looking at solutions already available and the pipeline of ideas.

First, solutions are likely to address the low-hanging fruit of routine, repetitive and largely administrative tasks, which absorb significant time of doctors and nurses, optimising healthcare operations and increasing adoption. In this first phase, we would also include Al applications based on imaging, which are already in use in specialties such as radiology, pathology and ophthalmology.

In the second phase, we expect more Al solutions that support the shift from hospital-based to home-based care, such as remote monitoring, Al-powered alerting systems or virtual assistants, as patients take increasing ownership of their care. This phase could also include a broader use of NLP solutions in the hospital and home setting, and more use of Al in a broader number of specialties, such as oncology, cardiology or neurology, where advances are already being made. This will require Al to be embedded more extensively in clinical workflows, through the intensive engagement of professional bodies and providers. It will also require well designed and integrated solutions to use existing technologies effectively in new contexts. This scaling up of Al deployment would be fuelled by a combination of technological advancements (e.g., in deep learning, NLP, connectivity etc.) and cultural change and capability building within organisations.


In the third phase, we would expect to see more AI solutions in clinical practice based on evidence from clinical trials, with increasing focus on improved and scaled clinical decision-support (CDS) tools in a sector that has learned lessons from earlier attempts to introduce such tools into clinical practice and has adapted its mindset, culture and skills. Ultimately respondents would expect to see AI as an integral part of the healthcare value chain, from how we learn, to how we investigate and deliver care, to how we improve the health of populations. Important preconditions for AI to deliver its full potential in European healthcare will be the integration of broader datasets across organisations, strong governance to continuously improve data quality, and greater confidence from organisations, practitioners and patients in both the AI solutions and the ability to manage the related risks.

How will AI change the healthcare workforce?

The MGI has studied how automation and AI are likely to affect the future of work. It concludes that automation will affect most jobs across sectors, but the degree varies significantly, and healthcare is one of the sectors with the lowest overall potential for automation – only 35 percent of time spent is potentially automatable and this varies by type of occupation. The potential for automation is different to the likelihood of adoption.

The analysis uses a midpoint scenario, which estimates that 15 percent of current work hours in healthcare are expected to be automated. Exhibit 2 shows the share of hours currently worked that could be freed up by automation by 2030 for a wide range of healthcare occupations in selected European countries. This does not reflect the potential for further disruption through other factors, such as personalisation, that may revolutionise healthcare by focusing on a "segment of one".

Exhibit 2 – Share of hours worked that could be freed up by automation by 2030 in selected European countries in the midpoint adoption scenario



How will automation and Al affect the number of jobs in healthcare? The reality is that the European healthcare sector faces a significant workforce gap that is only expected to widen. The World Health Organization estimates overall demand for healthcare workers to rise to 18.2 million across Europe by 2030 and, as an example, states that the current supply of 8.6 million nurses, midwives and healthcare assistants across Europe will not meet current or projected future need. The MGI analysis of the demand for specific types of healthcare activities suggests significant increases in the need for specific professionals, such as licenced practical and vocational nurses, home health aides and others, who are core to the day-to-day delivery of care to European citizens. It highlights that automation could, in fact, alleviate workforce shortages in healthcare, as demand for occupations is set to increase. For example, a 39 percent increase in all nursing occupations is expected by 2030, even allowing for the fact that approximately 10 percent of nursing activities could be freed up by automation.

The impact on the workforce will be much more than jobs lost or gained - the work itself will change. At the heart of any change is the opportunity to refocus on and improve patient care. Al can help remove or minimise time spent on routine, administrative tasks, which can take up to 70 percent of a healthcare practitioner's time. A recurring theme in interviews was that this type of Al role would not just be uncontroversial but would top of most people's wish list and would speed up adoption. Al can go further. It can augment a range of clinical activities and help healthcare practitioners access information that can lead to better patient outcomes and higher quality of care. It can improve the speed and accuracy in use of diagnostics, give practitioners faster and easier access to more knowledge, and enable remote monitoring and patient empowerment through self-care. This will all require bringing new activities and skills into the sector, and it will change healthcare education - shifting the focus away from memorising facts and moving to innovation, entrepreneurship, continuous learning and multidisciplinary working. The biggest leap of all will be the need to embed digital and AI skills within healthcare organisations - not only for physicians to change the nature of consultations, but for all frontline staff to integrate Al into their workflow. This is a significant change in organisational culture and capabilities, and one that will necessitate parallel action from practitioners, organisations and systems all working together.

The final effect on the workforce will be the introduction of new professionals. Multiple roles will emerge at the intersection of medical and data-science expertise. For example, medical leaders will have to shape clinically meaningful and explainable AI that contains the insights and information to support decisions and deepen healthcare professionals' understanding of their patients. Clinical engagement will also be required in product leadership, in order to determine the contribution of Albased decision-support systems within broader clinical protocols. Designers specialising in humanmachine interactions on clinical decision making will help create new workflows that integrate Al. Data architects will be critical in defining how to record, store and structure clinical data so that algorithms can deliver insights, while leaders in data governance and data ethics will also play vital roles. In other data-rich areas, such as genomics, new professionals would include 'hybrid' roles, such as clinical bioinformaticians, specialists in genomic medicine and genomic counsellors. Institutions will have to develop teams with expertise in partnering with, procuring and implementing Al products that have been developed or pioneered by other institutions. Orchestrating the introduction of new specialisations coming from data science and engineering within healthcare delivery will become a critical skill in itself. There will be an urgent need for health systems to attract and retain such scarce and valuable talent, for example, by developing flexible and exciting career paths and clear routes to leadership roles.

What needs to change to encourage the introduction and scaling of AI in healthcare?

The strides made in the field of AI in healthcare have been momentous. Moving to a world in which AI can deliver significant, consistent and global improvements in care will be more challenging.

Of course, Al is not a panacea for healthcare systems, and it comes with strings attached. The analyses in this report and the latest views from stakeholders and frontline staff reveal a set of themes that all players in the healthcare ecosystem will need to address:

1) Working together to deliver quality AI in healthcare. Quality came up in our interviews time and again, especially issues around the poor choice of use cases, AI design and ease of use, the quality and performance of algorithms, and the robustness and completeness of underlying data. The lack of multidisciplinary development and early involvement of healthcare staff, and limited iteration by joint AI and healthcare teams were cited as major barriers to addressing quality issues early on and adopting solutions at scale. The survey revealed this is driven by both sides: only 14 percent of startup executives felt that the input of healthcare professionals was critical in the early design phase; while the healthcare professionals saw the private sector's role in areas such as aggregating or analysing data, providing a secure space for data lakes, or helping upskill healthcare staff as minimal or nonexistent.

One problem AI solutions face is building the clinical evidence of quality and effectiveness. While startups are interested in scaling solutions fast, healthcare practitioners must have proof that any new idea will "do no harm" before it comes anywhere near a patient. Practitioners also want to understand how it works, where the underlying data come from and what biases might be embedded in the algorithms, so are interested in going past the concept of AI as a "black box" to understand what underpins it. Transparency and collaboration between innovators and practitioners will be key in scaling AI in European healthcare.

User-centric design is another essential component of a quality product. Design should have the end user at its heart. This means Al should fit seamlessly with the workflow of decision makers and by being used, it will be improved. Many interviewees agreed that if Al design delivers value to end users, those users are more likely to pay attention to the quality of data they contribute, thereby improving the Al and creating a virtuous circle. Finally, Al research needs to heavily emphasise explainable, causal and ethical Al, which could be a key driver of adoption.

2) Rethinking education and skills. We have already touched on the importance of digital skills – these are not part of most practitioners' arsenal today. All in healthcare will require leaders well-versed in both biomedical and data science. There have been recent moves to train students in the science where medicine, biology and informatics meet through joint degrees, though this is less prevalent in Europe. More broadly, skills such as basic digital literacy, the fundamentals of genomics, Al and machine learning need to become mainstream for all practitioners, supplemented by critical-thinking skills and the development of a continuous-learning mindset. Alongside upgrading clinical training, healthcare systems need to think about the existing workforce and provide ongoing learning, while practitioners need the time and incentive to continue learning.

3) Strengthening data quality, governance, security and interoperability. Both interviewees and survey respondents emphasised that data access, quality and availability were potential roadblocks. The data challenge breaks down into digitising health to generate the data, collecting the data, and setting up the governance around data management. MGI analyses show that healthcare is among the least digitised sectors in Europe, lagging behind in digital business processes, digital spend per worker, digital capital deepening and the digitisation of work and processes. It is critical to get the basic digitisation of systems and data in place before embarking on AI deployments – not least because the frustrations staff have with basic digitisation could spill over to the wider introduction of AI.

In addition, as more healthcare is delivered using new digital technologies, public concerns about how healthcare data are used have grown. Healthcare organisations should have robust and compliant data-sharing policies that support the improvements in care that AI offers while providing the right safeguards in a cost-efficient way. Physicians we interviewed emphasised that, given the volume of data required for AI, a poorly thought out process of anonymisation could be a major cost, making diagnostic algorithms prohibitively expensive.

Interviewees also emphasised, however, that both healthcare as a sector and Europe as a region have significant advantages. First, both healthcare organisations and health systems are used to dealing with sensitive data through well-structured data governance and risk-management processes. In some cases, healthcare could lead the way for other sectors seeking to put such measures in place. Secondly, Europe benefits from national health systems with extensive datasets, often shared within integrated care systems, offering a set of systems and processes to build on that could also serve as examples to other regions.

The final data challenge is getting datasets to talk to each other. Policy makers, funding bodies and nonprofit organisations need to support efforts to sufficiently anonymise and link data and, where sensible, to build databases that can be accessed by stakeholders with the appropriate safeguards. In order to make the most of the rich data that is available, healthcare systems need an interconnected data infrastructure. This is an area where Europe, as mentioned, could have a significant advantage, in terms of its extensive national datasets and its networks of innovations clusters or hubs and pan-European collaborations with academia and industry, providing a prototype for the creation of centres of excellence for AI in healthcare.

4) Managing change. Managing change while introducing Al is no different to managing change in complex institutions more broadly, but for healthcare, clinical leadership is key, as is being open to identifying the right use cases that support rather than antagonise practitioners and truly augment rather than substitute their ability to deliver the best possible care to their patients. This could include prioritising solutions that focus on reducing the time people spend on routine administrative tasks, rather than those that seek to act as virtual assistants who interact directly with patients, or CDS tools that facilitate activities physicians see as core to their professional role, i.e., the clinical diagnosis.

Healthcare providers also need to be transparent about the benefits and risks of Al and work with staff to harness the collective energy of their teams and capitalise on the opportunities Al can bring. It may not be a rapid process, but it soon becomes increasingly rewarding for practitioners and is an important part of the overall adoption process.

- 5) Investing in new talent and creating new roles. Healthcare organisations need to consider how they will develop and recruit the new roles that will be critical to the successful introduction and adoption of AI, such as data scientists or data engineers. Demand for such skills is heating up across industries and the competition for talent will be fierce, but many young data professionals find a true vocation in healthcare and its mission and are excited about the potential of digital health and AI. Developing flexible, agile models to attract and retain such talent will be a key part of these organisations' people strategy.
- 6) Working at scale. The lessons from public- and private-sector actors aiming to develop AI in healthcare to date suggest that scale matters largely due to the resources needed to develop robust AI solutions or make them cost-efficient. Not every hospital will be able to afford to attract new AI talent, or have access to enough data to make algorithms meaningful. Smaller organisations can benefit from working in innovation clusters that bring together AI, digital health, biomedical research, translational research or other relevant fields. Larger organisations can develop into centres of excellence that pave the way for regional and public-private collaborations to scale AI in European healthcare.
- 7) Regulation, policy making and liability, and managing risk. Responsibility for Al solutions both clinical and technical is split today between healthcare organisations and their staff. Interviewees emphasised the importance of clarifying whether Al will be regulated as a *product* or as a *tool* that supports decision making, and of introducing a consistent regulatory approach for Al similar to that provided by the European Medicines Agency (EMA) on medicines or by national authorities on medical devices. Another issue to be clarified across Europe is the extent to which patients' access to some Al tools needs to be regulated or restricted to prescription. The issue of liability and risk management is a particular challenge. Patient safety is paramount, but healthcare providers also have to think about the professional accountability of their clinicians, as well the protection of their organisations from reputational, legal or financial risk. Healthcare lawyers interviewed in this report were clear that accountability ultimately rests with the clinician under current laws. Innovators are also proactively addressing related risks. Many are putting new processes in place and ensuring a "compliance by design" approach is at the core of product development.
- 8) Funding. The reimbursement of medicines and medical devices across Europe is complicated and is even less clear when it comes to AI solutions. The responsibility for decisions on the reimbursement of a medicine or device rests with national and local payor organisations depending on the country, and this decision usually covers what will be reimbursed and at what price. Clear criteria for the potential reimbursement of AI applications will be crucial for its adoption at scale, alongside creative funding models that ensure the benefits are shared across organisations.

What this could mean for healthcare organisations

European healthcare providers need to assess what their distinctive role or contribution can be in introducing or scaling Al in healthcare. They need to take stock of their capabilities, level of digitisation, availability and quality of data, resources and skills and then define their level of ambition for Al as it fits with their strategic goals. They should also define the enablers they need to put in place. These could include creating an Al ecosystem through partnerships to codevelop the right solutions for their population; codeveloping a compelling narrative on Al with patients and practitioners; defining and developing the right use cases jointly with end users; defining and addressing skill gaps in digital literacy for their staff; refining their value proposition for Al talent; addressing data-quality, access, governance and interoperability issues; and shaping a culture of entrepreneurship. All these themes were echoed by the healthcare professionals in the survey, who listed the top three things healthcare organisations could do, as: bringing together multidisciplinary teams with the right skills, improving the quality and robustness of data and identifying the right use cases.

What this could mean for health systems

European health systems can play a more fundamental role in catalysing the introduction and scaleup of Al. Key actions they could take include:

- Develop a regional or national AI strategy for healthcare, defining a medium- and longer-term
 vision and goals, specific initiatives, resources and performance indicators. Define use cases
 to support through targeted funding and incentives to enable scaling of AI solutions across the
 system; ensure these deliver against both clinical and operational outcomes.
- Set standards for digitisation, data quality and completeness, data access, governance, risk
 management, security and sharing, and system interoperability; incentivise adherence to
 standards through a combination of performance and financial incentives.
- Redesign workforce planning and clinical-education processes to address the needs of both
 future healthcare and Al-focused professionals; and invest upfront in upskilling frontline staff
 and designing lifelong-learning programmes through continuing professional development and
 degrees or diplomas for healthcare professionals.
- Provide incentives and guidance for healthcare organisations to collaborate in centres of excellence/clusters of innovation at the regional or national level.
- Address AI regulation, liability and funding issues, creating the right environment for appropriate, safe and effective AI solutions to be adopted but minimising the risk to practitioners.
- Ensure this is reflected in funding and reimbursement mechanisms for innovation in healthcare

 the number one priority for survey respondents from health systems, alongside simplifying data-governance and data-sharing processes.

What this could mean for Europe

Our early analyses of levels of VC investment and Al-related clinical trials, as well as the number of companies and M&A deals in digital health and Al, show this is a fast-moving market where Europe, as a group of countries, plays a growing role internationally alongside the US and China. The scale needed to effectively roll out Al in healthcare may place a toll on smaller EU Member States but could be easily reached through collaborations across Europe. Interviewees and survey respondents were clear on the potential impact of the EU in helping deliver the promise of Al, faster and at a greater scale for Europe's population. They highlighted the following specific strands of work that could be considered:

- Consolidating funding against strategic Al priorities. Defining a few concrete priorities for Al in European healthcare and consolidating funding to support them strategically could provide a much-needed stimulus to fast-track promising developments in Al for healthcare.
- Creating a level playing field across Europe. Common standards on data, regulation, access, privacy or interoperability, and shared requirements on data exchange, would enable innovators to scale Al solutions cost-effectively, while focusing their energies on entrepreneurship. It would also enable patients, practitioners and health systems to develop the same confidence in new Al solutions that they have now in new medicines and medical devices that have undergone European approval.
- Clarifying key aspects of regulation around product approval, accountability, governance and litigation. The EU can help remove barriers to adopting AI at the national and local level, providing clarity on approval processes across Europe, potentially creating regulatory centres of excellence for AI regulation, and setting expectations on accountability and liability.
- Encouraging and supporting the creation of centres of excellence for Al in healthcare. This can help consolidate scarce Al talent in high-profile and agile networks that can move quickly from design to implementation and spearhead the introduction of new capabilities in national health systems. These centres of excellence would also lead the way in adopting and implementing technologies and approaches developed elsewhere. Indeed, their expertise in applying approaches to improve care will be as critical as their expertise in developing those approaches in the first place. They can also ensure that talent creation and continuous learning are prioritised and enhanced at the European level.
- Playing an active role in Al. This will ensure that the thoughtful European approach to ethics, health data and patient confidentiality shapes the Al sector, in the same way that GDPR has for privacy protection.

Overall, this report highlights the excitement of Europe-wide stakeholders, healthcare professionals, investors and innovators about the impact of AI on European healthcare, and about the thoughtful approach taken across Europe to ensure this delivers ethical and trustworthy AI. It also highlights that this is only the latest view across Europe and internationally – speed is of the essence if Europe is to continue playing a leading role in shaping the AI of the future to deliver its true potential to European health systems and their patients.

